Inflammation Signs and Symptoms
Conditions
Interventions
Current intervention as of 22/07/2022:
Participants will be randomized to the treatment arms through an interactive voice or web-based response system (IxRS). In this single-ascending dose (SAD) study
Sponsors
Genentech, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age =18 years and =75 years 2. Ability to comply with the study protocol, in the investigator’s judgment 3. Use of contraceptive measures
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding, or intending to become pregnant during the study or within 85 days after the dose of RO7303509 2. No comorbid conditions that may interfere with the evaluation of an investigational medical product 3. No history or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, or have an impact on the study results 4. History of severe allergic or anaphylactic reactions to human, humanized, or Current treatment with medications that are well known to prolong the QT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The safety of single doses of RO7303509 according to the World Health Organization (WHO) Toxicity Grading Scale and vital signs, labs and ECG from baseline to day 85 | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
United States of America
Outcome results
None listed